Home > Insider Trading > Filing (0001127602-23-024445)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1492422	Apellis Pharmaceuticals Inc.	APLS	Pharmaceutical Preparations (2834)	271537290

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1827317	Nur Nicholson	C/O Apellis Pharmaceuticals, Inc. 100 Fifth Avenue, 3Rd Floor Waltham MA 02451	Chief Technical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-09-18	9,719	$29.76	73,634	No	4	M	Direct
Common Stock	Disposition	2023-09-18	9,719	$42.21	63,915	No	4	S	Direct
Common Stock	Disposition	2023-09-18	10,631	$46.15	53,284	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2023-09-18	9,719	$0.00	9,719	$29.76

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
115,281		2030-08-16	No	4	M	Direct

Footnotes

This transaction was executed in multiple trades at prices ranging from $46.200 - $46.250. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $46.140 - $46.240. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This includes 412 shares from 04/30/2023 ESPP purchase.
This stock option was granted on August 17, 2020 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service.